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The RLF-B component of the replication licensing system is
distinct from Cdc6 and functions after Cdc6 binds to chromatin
Shusuke Tada*†, James P.J. Chong†‡, Hiro M. Mahbubani† and J. Julian Blow*†
Replication licensing factor (RLF) is an essential
initiation factor that can prevent re-replication of DNA
in a single cell cycle [1,2]. It is required for the
initiation of DNA replication, binds to chromatin early
in the cell cycle, is removed from chromatin as DNA
replicates and is unable to re-bind replicated
chromatin until the following mitosis.
Chromatography of RLF from Xenopus extracts has
shown that it consists of two components termed
RLF-B and RLF-M [3]. The RLF-M component consists
of complexes of all six Xenopus minichromosome
maintenance (MCM/P1) proteins (XMcm2–7), which
bind to chromatin in late mitosis and are removed as
replication occurs [3–7]. The identity of RLF-B is
currently unknown. At least two factors must be
present on chromatin before licensing can occur: the
Xenopus origin recognition complex (XORC) [8,9] and
Xenopus Cdc6 (XCdc6) [10]. XORC saturates Xenopus
sperm chromatin at approximately one copy per
replication origin whereas XCdc6 binds to chromatin
only if XORC is bound first [9–11]. Although XORC
has been shown to be a distinct activity from RLF-B
[9], the relationship between XCdc6 and RLF-B is
currently unclear. Here, we show that active XCdc6 is
loaded onto chromatin in extracts with defective RLF,
and that both RLF-M and RLF-B are still required for
the licensing of XCdc6-containing chromatin.
Furthermore, RLF-B can be separated from XCdc6 by
immunoprecipitation and standard chromatography.
These experiments demonstrate that RLF-B is both
functionally and physically distinct from XCdc6, and
that XCdc6 is loaded onto chromatin before RLF-B
function is executed.
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Results and discussion
In order to explore different activities required for licens-
ing, we immunodepleted Xenopus egg extracts with anti-
bodies specific for XOrc1 (to remove XORC), XCdc6 or
XMcm3 (to remove RLF-M); non-immune serum was used
as a negative control. Extracts were also treated with the
kinase inhibitor 6-dimethylaminopurine (6-DMAP), as
described [12], to generate a ‘6-DMAP extract’ that is func-
tionally devoid of RLF activity. Xenopus sperm nuclei were
incubated briefly in these extracts to allow proteins to load
onto the DNA, and the chromatin was then isolated and
immunoblotted with antibodies against XOrc1 and XCdc6
(Figure 1a). Consistent with previous reports [9–11], both
XOrc1 and XCdc6 were assembled onto chromatin in the
non-immune control extract (NI–) and extracts without a
functional RLF (XMcm3-depleted or 6-DMAP-treated
extracts), but XCdc6 was not loaded onto chromatin lacking
XORC. In parallel, we measured the ability of the different
extracts to license sperm nuclei (Figure 1b, white bars).
Although efficient licensing occurred in extracts mock-
depleted with non-immune antibodies, licensing did not
occur in buffer or in extracts immunodepleted of either
XOrc1, XCdc6 or XMcm3. This demonstrates that, consis-
tent with previous reports [3,4,9–11], XORC, XCdc6 and
XMcm3 are all independently required for licensing naive
sperm nuclei. We next determined whether the XORC and
XCdc6 assembled onto chromatin in the XMcm3-depleted
extract (XMcm3– chromatin) or in the 6-DMAP-treated
extract (6-DMAP chromatin) were functional. Chromatin
templates were assembled in the XMcm3-depleted or
6-DMAP-treated extract and were then isolated and incu-
bated for a second time in either buffer or in another
immunodepleted extract, before being subjected to a func-
tional licensing assay (Figure 1b). Both XMcm3– chromatin
and 6-DMAP chromatin were efficiently licensed on subse-
quent incubation in XOrc1-depleted or XCdc6-depleted
extract, but not on incubation in buffer or in the XMcm3-
depleted extract (Figure 1b). This demonstrates that,
despite being unlicensed, chromatin assembled in either
the XMcm3-depleted extract or in the 6-DMAP extract
contains active XORC and XCdc6.
We have previously shown that RLF-M and RLF-B can
be separated by differential precipitation with polyethyl-
ene glycol (PEG) [3,13]. We therefore prepared unli-
censed chromatin by isolating Xenopus sperm chromatin
after incubation in either XMcm3-depleted extract or in
6-DMAP-treated extract. We next determined which RLF
components are required for the licensing of this XMcm3–
chromatin and 6-DMAP chromatin. Figure 2 shows that
only when these chromatin templates were incubated with
both RLF-B and RLF-M fractions did they become func-
tionally licensed. Given that both XMcm3– chromatin and
6-DMAP chromatin contain functional XORC and XCdc6
and could be licensed in XOrc1-depleted or XCdc6-
depleted extract (Figure 1), this demonstrates that RLF-B
is an essential component of the licensing system that is
functionally distinct from both XORC and XCdc6. The
requirement for RLF-B in the licensing of chromatin
assembled in XMcm3-depleted extract also demonstrates
that RLF-B is not simply required to reverse an abnormal
effect that occurs in the 6-DMAP-treated extract, but is
likely to represent a physiological activity required for the
licensing of chromatin in a normal cell cycle.
We then investigated whether the different RLF-B and
XCdc6 activities are physically distinct and whether they
can be separated from one another. The fractionation of
RLF-B over three sequential chromatographic steps (PEG
precipitation, phosphocellulose chromatography and ammo-
nium-sulphate precipitation) has been described previously
[9,13]. The resultant fraction (called ‘BPAS’) contains both
XORC and XCdc6 in addition to RLF-B ([9] and see later).
The BPAS fraction was immunodepleted using either anti-
bodies to XCdc6 or non-immune antibodies and the resul-
tant material was then assayed for XCdc6 activity
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Figure 1
Unlicensed chromatin contains active XORC and XCdc6. (a) Xenopus
sperm nuclei were left untreated (sperm), or were incubated for 15 min
in Xenopus interphase extracts previously immunodepleted with
antibodies against XOrc1 (XOrc1–), XCdc6 (XCdc6–) or XMcm3
(XMcm3–), or with non-immune antibodies (NI–), or were incubated in
6-DMAP-treated extract. Chromatin was isolated and subjected to
SDS–PAGE and immunoblotted with antibodies against XOrc1 and
XCdc6. (b) A schematic representation of the experimental procedure
is shown on top. Untreated sperm chromatin (sperm) or sperm
chromatin previously assembled in either 6-DMAP-treated extract
(6-DMAP chromatin) or in XMcm3-depleted extract (XMcm3–
chromatin) was isolated and incubated in buffer or in a second aliquot
of extract previously immunodepleted with antibodies against XOrc1,
XCdc6 or XMcm3, or with non-immune antibodies, before being
transferred to 6-DMAP-treated extract and incubated for a further
90 min with [α-32P]dATP to assess the degree of licensing.
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Figure 2
RLF-B and RLF-M are both required for the licensing of 6-DMAP and
XMcm3– chromatin. A schematic representation of the experimental
procedure is shown on top. Sperm chromatin previously assembled in
either 6-DMAP-treated extract (6-DMAP chromatin) or in XMcm3-
depleted extract (XMcm3– chromatin) was isolated and incubated in
combinations of PEG-cut fractions that contained (+) or lacked (–)
RLF-B or RLF-M, or in untreated extract (whole extract), before being
transferred to 6-DMAP-treated extract and incubated for a further
90 min with [α-32P]dATP to assess the degree of licensing.
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(Figure 3a) and RLF-B activity (Figure 3b). As shown in
Figure 3, the BPAS fraction had both XCdc6 and RLF-B
activity. The XCdc6 activity was completely removed by
depletion with anti-XCdc6 antibodies (Figure 3a). In con-
trast, the RLF-B activity of the BPAS fraction was not
reduced by the depletion of XCdc6 (Figure 3b), showing
that RLF-B had been separated from XCdc6.
As an alternative method of separating RLF-B and XCdc6,
we chromatographed the BPAS fraction on phenyl
Sepharose. A peak of RLF-B activity eluted at around
500 mM KCl (Figure 4a, fractions 21–25) representing more
than 90% of the activity loaded onto the column. In con-
trast, XOrc1 and XCdc6 were not eluted until much lower
salt concentrations, with the majority of XOrc1 and XCdc6
remaining bound to the column under these low salt condi-
tions (Figure 4b and data not shown). No XCdc6 could be
detected in the fractions containing RLF-B activity (note
that a very long exposure of the immunoblot is shown in
Figure 4b and that 25 times less material was loaded in the
BPAS lane (L) than in the individual fractions). Although
the BPAS fraction loaded onto the phenyl Sepharose
column could restore activity to a XCdc6-depleted extract
(Figure 4c), there was insufficient XCdc6 in either the
RLF-B peak (fraction 23) or even in the last fraction of the
elution (fraction 31) to provide any XCdc6 activity
(Figure 4c). This demonstrates a clear physical separation of
RLF-B and XCdc6 by standard chromatography.
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Figure 3
Immunodepletion of XCdc6 from partially purified RLF-B. The BPAS
fraction was prepared and then immunodepleted with anti-XCdc6
antibodies (XCdc6–) or with an equivalent quantity of non-immune
antibody (NI–). The resultant material was then compared with buffer
alone or with untreated BPAS in assays for (a) XCdc6 activity or
(b) RLF-B activity. (a) Aliquots were added directly to XCdc6-depleted
extract. Sperm nuclei were then incubated in each aliquot for 15 min,
before being transferred to 6-DMAP-treated extract and incubated for
a further 90 min with [α-32P]dATP to measure the rescue of XCdc6
activity. The dashed line shows the amount of licensing observed in
non-immune-depleted extract. (b) Aliquots were incubated with partially
purified RLF-M and 6-DMAP chromatin for 15 min, before being
transferred to 6-DMAP-treated extract and incubated for a further
90 min with [α-32P]dATP to measure the RLF-B activity.
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Figure 4
Separation of RLF-B and XCdc6 by hydrophobic chromatography. The
BPAS fraction, containing both RLF-B and XCdc6, was fractionated
on phenyl Sepharose. (a) Chromatography profile, showing the RLF-B
activity of individual fractions (squares) and the KCl elution gradient
(solid line). The RLF-B assay was performed by incubating diluted
column fractions with partially purified RLF-M and 6-DMAP chromatin
for 15 min, before being transferred to 6-DMAP-treated extract and
incubated for a further 90 min with [α-32P]dATP. The dotted (lower)
line shows the background activity of buffer alone, whereas the dashed
(upper) line shows the activity of the starting BPAS fraction at a
comparable dilution. (b) Half of each fraction was precipitated using
deoxycholate–trichloroacetic acid, electrophoresed and then
immunoblotted with antibodies against XOrc1 and XCdc6. Fraction L
is 2% of the BPAS sample that was loaded onto the phenyl Sepharose
column. (c) Aliquots of either crude extract, the starting BPAS fraction,
or fractions 23 or 31 from the phenyl Sepharose column were added
directly to the extract immunodepleted of XCdc6. Sperm nuclei were
then incubated in each aliquot for 15 min, before being transferred to
6-DMAP-treated extract and incubated for a further 90 min with
[α-32P]dATP to measure the rescue of XCdc6 activity.
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In addition to the experiments shown here demonstrating
a clear functional and physical separation of RLF-B from
XCdc6, we have also observed that recombinant XCdc6
protein can restore licensing activity to XCdc6-depleted
extract, but provides no RLF-B activity (see Supplemen-
tary material published with this article on the internet).
We are currently attempting to complete the purification
of RLF-B in order to identify it and understand its func-
tion. Despite it being unidentified, the results shown
here strongly suggest that RLF-B acts in concert with
RLF-M on chromatin that already contains XORC and
XCdc6. Figure 2 shows that both RLF-M and RLF-B are
required for the licensing of chromatin previously assem-
bled in an XMcm3-depleted extract. Because XMcm3-
depleted extract contains active RLF-B [3], this
demonstrates that RLF-B cannot execute its essential
function before RLF-M loading. Given that XCdc6 must
be loaded onto chromatin prior to RLF-M ([10];
Figure 1), these experiments also show that the essential
function of RLF-B in licensing can only be executed after
XCdc6 has bound to chromatin.
Materials and methods
Preparation of egg extracts
Metaphase-arrested Xenopus egg extracts were prepared as described
[13]. For replication assays, they were supplemented with 100 µg/ml
cycloheximide, 25 mM phosphocreatine, 15 µg/ml creatine phosphoki-
nase and [α-32P]dATP, and were then released into interphase with
0.3 mM CaCl2. The RLF-defective 6-DMAP extract was prepared in a
similar way, except that 3 mM 6-DMAP was added prior to CaCl2-stimu-
lated release [12,13]. Immunodepletion of interphase extracts or the
BPAS fraction with antibodies raised against XOrc1 [9], XCdc6 [10] or
XMcm3 [5], or with antibodies from non-immune rabbit serum, was per-
formed as described [13]. Control extracts were diluted with an equiva-
lent amount of buffer. As soon as immunodepletion was complete,
extracts were snap frozen in liquid nitrogen in 10 µl aliquots for future use. 
Chromatin templates
Demembranated Xenopus sperm nuclei were prepared as described
[13]. They were assembled into chromatin by incubation for 15 min at
23°C in 6-DMAP extracts at 20,000–40,000 nuclei per µl (50–100 ng
DNA per µl) or in immunodepleted extracts at 10,000–13,000 nuclei per
µl (25–30 ng DNA per µl). The extract was then diluted 10-fold in nuclear
isolation buffer [13] (NIB: 50 mM KCl, 50 mM Hepes-KOH pH 7.6, 5 mM
MgCl2, 2 mM DTT, 0.5 mM spermine 3HCl, 0.15 mM spermine 4HCl,
1 µg/ml of each of aprotinin, leupeptin and pepstatin) supplemented with
2.5 mM Mg–ATP and 0.01% Triton-X-100, and then underlayered with
the same buffer containing 15% sucrose. Chromatin was then pelleted at
1,500 × g in a swinging bucket centrifuge for 5 min at 4°C, and was
resuspended in NIB supplemented with 2.5 mM Mg–ATP and 0.01%
Triton-X-100. Aliquots of pelleted chromatin were either used for replica-
tion assays or immunoblotted by standard techniques using 10%
SDS–PAGE and ECL visualisation (Amersham).
Chromatography
The BPAS fraction was prepared as described [9,13]. For phenyl
Sepharose chromatography, BPAS was made 1 M with respect to KCl
in Hepes buffer (20 mM Hepes-KOH pH 8, 10% sucrose, 1 µg/ml of
each of aprotinin, leupeptin and pepstatin) and applied to a 1 ml HiTrap
phenyl Sepharose column (Pharmacia) equilibrated in the same buffer.
The column was developed with a gradient over three column volumes
to Hepes buffer without KCl. In order to overcome the inhibitory effect
of the high salt on the RLF-B and XCdc6 assays, aliquots were diluted
five-fold with Hepes buffer prior to assay. For blotting, aliquots were
precipitated using DOC–TCA as follows: 50% of each sample was
supplemented with 0.015% deoxycholate, mixed and incubated for
10 min at room temperature, supplemented with 5% trichloroacetic
acid, mixed and microfuged for 5 min. The supernatant was removed
and the pellet was resuspended in 0.01 N NaOH.
Replication assays
DNA synthesis was measured by the incorporation of [α-32P]dATP into
acid-insoluble material as described [13]. Licensing assays were per-
formed by measuring DNA synthesis in 6-DMAP-treated extract as
described [3,13]. Briefly, 0.3 µl chromatin templates were incubated with
2 µl assay fractions for 15 min. The reaction was then supplemented with
5.7 µl 6-DMAP extract containing [α-32P]dATP and the incubation con-
tinued for a further 90 min, after which time the total amount of DNA syn-
thesis was measured. All incubations were performed at 23°C.
Supplementary material
A figure showing that recombinant XCdc6 does not have RLF-B activ-
ity is published with this paper on the internet.
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S1Supplementary material
Figure S1
Recombinant XCdc6 does not have RLF-B activity. Insect cells were
either infected with a histidine-tagged XCdc6 construct (recombinant
XCdc6) or were mock infected (mock infected). Cell lysates were
prepared and purified by nickel–agarose chromatography. Eluted
material was compared with either buffer alone or unfractionated egg
extract in assays for (a) XCdc6 activity or (b) RLF-B activity.
(a) Xenopus interphase egg extract was immunodepleted with anti-
XCdc6 antibodies and 1 µl of the depleted extract was supplemented
with 1 µl of the different fractions and incubated with Xenopus sperm
nuclei for 20 min. Samples were then added to 5.7 µl 6-DMAP-treated
extract containing [α-32P]dATP and the total DNA synthesis occurring
over 90 min was measured. (b) 6-DMAP chromatin was incubated in
1 µl RLF-M supplemented with 1 µl of the different fractions for
20 min. Samples were then added to 5.7 µl 6-DMAP-treated extract
containing [α-32P]dATP and the total DNA synthesis occurring over
90 min was measured.
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